

Special Issue

Novel Non-genomic Mechanism-Based Therapy against Melanoma

Message from the Guest Editor

Despite pioneering advances in the treatment of cutaneous melanoma with MAPK antagonists and immune-checkpoint inhibitors, it remains one of the most therapy-resistant malignancies. Additional therapeutic avenues must be identified to both maximize treatment effect and eradicate inherently resistant subpopulations of melanoma cells that are resistant to treatment and prevent the emergence and development of residual disease. An growing body of evidence supports the assumption of dynamic non-genomic mechanisms in melanoma cells involved in tumor heterogeneity leading to disease development, progression, sustained survival under treatments and drug resistance to cancer treatment. This Special Issue will address upcoming developments of new molecular and pharmacological strategies targeting adaptive response characteristics, becoming an exploitable therapeutic vulnerability to prevent the establishment of residual disease leading to relapse. Original research articles and communications as well as review articles are welcome.

Guest Editor

Dr. Mickaël Ohanna

Université Côte d'Azur, INSERM, C3M, 06204 Nice, France

Deadline for manuscript submissions

closed (20 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/132470

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)